Summit acquires Discuva

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) acquired antibiotic company Discuva Ltd. (Cambridge, U.K.), including its genetics-based SATIN antibiotics platform, for L5 million ($6.7 million) in cash and L5 million in Summit shares.

Discuva’s SATIN uses high throughput phenotypic screens to detect antibacterial activity and provide information about the molecular target and possible mechanisms of resistance (see BioCentury, March 17, 2014)...